| scholarly article | Q13442814 |
| P50 | author | Douglas Cines | Q16204220 |
| John P Atkinson | Q88032294 | ||
| Vladimir R Muzykantov | Q89339994 | ||
| Mortimer Poncz | Q124218035 | ||
| Ronald Carnemolla | Q125229991 | ||
| Maria Kowalska | Q67196707 | ||
| P2093 | author name string | Bi-Sen Ding | |
| Charles T Esmon | |||
| Michael Neyman | |||
| Samira Tliba | |||
| Dirk Spitzer | |||
| Sergei Zaitsev | |||
| Aaron Stonestrom | |||
| P2860 | cites work | Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective | Q24293646 |
| An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators | Q28254763 | ||
| The cytoprotective protein C pathway | Q28274500 | ||
| Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3 | Q28587775 | ||
| The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage | Q28588149 | ||
| Efficacy and safety of recombinant human activated protein C for severe sepsis | Q29547839 | ||
| Thrombin signalling and protease-activated receptors | Q29619601 | ||
| Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis | Q30444430 | ||
| Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots | Q30483038 | ||
| Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation | Q30489456 | ||
| Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis | Q33714889 | ||
| Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation | Q33944248 | ||
| Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial | Q79292898 | ||
| Amplified anticoagulant activity of tissue factor-targeted thrombomodulin: in-vivo validation of a tissue factor-neutralizing antibody fused to soluble thrombomodulin | Q80213978 | ||
| Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B | Q81333617 | ||
| Do-all receptor takes on coagulation, inflammation | Q81718324 | ||
| Cooperative action between band 3 and glycophorin A in human erythrocytes: immobilization of band 3 induced by antibodies to glycophorin A. | Q34115376 | ||
| Thrombin domains: structure, function and interaction with platelet receptors | Q34291931 | ||
| Structure and interaction modes of thrombin | Q34494865 | ||
| Inflammation and thrombosis | Q35181574 | ||
| Thrombomodulin. | Q35181628 | ||
| Thrombin interactions | Q35217254 | ||
| Red blood cell glycophorins. | Q35362789 | ||
| Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions | Q35597837 | ||
| Activated protein C and ischemic stroke | Q35760626 | ||
| Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature | Q35848131 | ||
| Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature | Q36445835 | ||
| Inflammation and the activated protein C anticoagulant pathway | Q36467895 | ||
| Reduced red blood cell destruction by antibody fragments | Q36701838 | ||
| Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells | Q36851476 | ||
| The nature and abundance of human red cell surface glycoproteins | Q37799405 | ||
| Thrombomodulin and its role in inflammation. | Q37909178 | ||
| Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture | Q41946791 | ||
| Glycophorin A dimerization and band 3 interaction during erythroid membrane biogenesis: in vivo studies in human glycophorin A transgenic mice | Q43582783 | ||
| Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death | Q45124371 | ||
| Cutting edge: treatment of complement regulatory protein deficiency by retroviral in vivo gene therapy | Q45862908 | ||
| Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment | Q45864060 | ||
| Intravascular coagulation activation in a murine model of thrombomodulin deficiency: effects of lesion size, age, and hypoxia on fibrin deposition. | Q47275663 | ||
| Crosstalk between inflammation and thrombosis | Q47814059 | ||
| Capillary endothelial thrombomodulin expression and fibrin deposition in rats with continuous and bolus lipopolysaccharide administration. | Q51836227 | ||
| Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets | Q53934182 | ||
| Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. | Q54483487 | ||
| Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure | Q64379178 | ||
| A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice | Q69820009 | ||
| Modulation of human endothelial thrombomodulin by neutrophils and their release products | Q72991619 | ||
| Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes | Q73621576 | ||
| ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement | Q75270684 | ||
| Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin | Q75424151 | ||
| Thrombin | Q77054123 | ||
| Association between decreased pulmonary endothelial cell thrombomodulin and local fibrin deposition in pneumonia | Q77325357 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4779-4785 | |
| P577 | publication date | 2012-04-04 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis | |
| P478 | volume | 119 |
| Q37132620 | Advanced drug delivery systems for antithrombotic agents. |
| Q87606536 | Biocompatible coupling of therapeutic fusion proteins to human erythrocytes |
| Q51809883 | Cell painting with an engineered EPCR to augment the protein C system. |
| Q26801300 | Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier |
| Q39011174 | Drug delivery by erythrocytes: "Primum non nocere". |
| Q97423962 | Enhancement of the blood-circulation time and performance of nanomedicines via the forced clearance of erythrocytes |
| Q38642538 | Erythrocyte-based drug delivery in Transfusion Medicine: Wandering questions seeking answers |
| Q38972974 | Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond |
| Q38218799 | Erythrocytes-based synthetic delivery systems: transition from conventional to novel engineering strategies |
| Q49351130 | Nanoparticle Properties Modulate Their Attachment and Effect on Carrier Red Blood Cells |
| Q37252049 | Platelet endothelial cell adhesion molecule targeted oxidant-resistant mutant thrombomodulin fusion protein with enhanced potency in vitro and in vivo |
| Q58792339 | Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis |
| Q92669248 | Recombinant human thrombomodulin attenuated sepsis severity in a non-surgical preterm mouse model |
| Q38117276 | Recombinant thrombomodulin of different domains for pharmaceutical, biomedical, and cell transplantation applications |
| Q93087990 | Red Blood Cell Membrane Processing for Biomedical Applications |
| Q38053177 | Red blood cells and polyelectrolyte multilayer capsules: natural carriers versus polymer-based drug delivery vehicles |
| Q38760096 | Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems |
| Q47336012 | Site-Specific Modification of Single-Chain Antibody Fragments for Bioconjugation and Vascular Immunotargeting. |
| Q40455117 | Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury. |
| Q28550941 | The Effect of Polymeric Nanoparticles on Biocompatibility of Carrier Red Blood Cells |
| Q38828458 | The role of complement activation in thrombosis and hemolytic anemias |
| Q91062652 | The transcription factor ERG regulates a low shear stress-induced anti-thrombotic pathway in the microvasculature |
| Q38100652 | Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects |
Search more.